Companies › Shanghai Bao Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 2; Genitourinary, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KJ101 Enzymatic debriding agent | – | Phase 2 | Burn | – |
| KJ103 for Injection | – | Phase 2 | Anti-Glomerular Basement Membrane Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06607016 | KJ103 for Injection | Phase 2 | Anti-Glomerular Basement Membrane Disease | Genitourinary | Dec 2025 |
| NCT07025408 | KJ101 | Phase 2 | Burn | Other | Mar 2026 |
No annotated target.
–
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Akebia Therapeutics Angitia Zynerba Pharmaceuticals Juro Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.